| name | es-cushing-against-treatment-no-diagnosis |
| description | This skill recommends against initiating cortisol-lowering treatment when there is no established diagnosis of Cushing's syndrome. It is triggered when a clinician considers treating suspected CS based only on borderline biochemical abnormalities or nonspecific signs without confirmatory testing; examples include "suspected CS", "borderline UFC", "no confirmed diagnosis", "consider empiric ketoconazole". |
Against Treatment Without Established Cushing's Syndrome Diagnosis
STEP 1 — Gather Information
Collect history of CS signs (central obesity, facial plethora, proximal muscle weakness, easy bruising, violaceous striae) and symptoms (hypertension, diabetes, osteoporosis, psychiatric changes). Perform initial biochemical screening: 24‑h urine free cortisol, late‑night salivary cortisol, or 1‑mg overnight dexamethasone suppression test. Note any cyclic patterns; do not rely on a single borderline result.
STEP 2 — Rule In / Rule Out
Is there an established diagnosis of Cushing's syndrome confirmed by at least two abnormal biochemical tests or one abnormal test with typical clinical features?
- YES → Proceed to treatment planning.
- NO → Do not start cortisol‑lowering therapy.
STEP 3 — Classify or Stratify
When diagnosis is not established, determine whether specific CS signs/symptoms are present.
- Specific signs/symptoms present → Pursue further diagnostic workup (repeat testing, dexamethasone‑CRH test, inferior petrosal sinus sampling) before considering treatment.
- Only borderline biochemical abnormality without specific signs → Recommend against treatment and observe or repeat testing.
STEP 4 — Decide
Do not initiate medication, surgery, or radiation aimed at lowering cortisol. Instead, arrange follow‑up biochemical testing in 3–6 months, evaluate for cyclic CS, and treat comorbidities (e.g., hypertension, diabetes) with standard therapies.
Clinical Guardrails / Mimics / Pitfalls
Do not treat based on a single borderline UFC or late‑night salivary cortisol; avoid empiric ketoconazole, metyrapone, or mifepristone without confirmed CS, as this can cause iatrogenic adrenal insufficiency. Recognize that isolated hypertension or diabetes may mimic CS but require standard management. Beware of cyclic CS where a single normal test does not exclude disease.
Concrete Clinical Example
A 45‑year‑old woman with mild hypertension and a UFC 1.2× upper limit of normal (borderline) but no facial plethora, proximal weakness, or striae considers starting ketoconazole. The skill advises against treatment, recommends repeat UFC and late‑night salivary cortisol in 1 month, and to manage hypertension with an ACE inhibitor pending clarification.
Source: Treatment of Cushing’s Syndrome: An Endocrine Society Clinical Practice Guideline, Nieman et al., Endocrine Society, 2015, DOI: 10.1210/jc.2015-1818
